CommercialCoverageMedium impact
Vitiligo (CPB 0422, reviewed 2026-07-16)
Aetna·Dermatology·Medical Policy
We identified it
Aug 19, 2026
Summary
Aetna updated its vitiligo treatment policy (CPB 0422) to establish medical necessity criteria for photochemotherapy, excimer laser, and narrow-band UVB therapies, requiring documented inadequate response to topical tacrolimus, corticosteroids, or ruxolitinib before approval. The policy designates numerous treatments as experimental/investigational (including JAK inhibitors combined with UVB, CAR-T therapy, rituximab, and various grafting techniques) and classifies micropigmentation and depigmentation as cosmetic, not covered.
Action Required
Immediately: Billing and prior authorization teams must implement the following: (1) For CPT 96900, 96912, 96913, and 96999 (phototherapy and excimer laser): Require documentation of failed prior therapy (topical tacrolimus, corticosteroids, or ruxolitinib) before claim submission. Add medical necessity validation to billing software. (2) For CPT 96900/96913 continuation: Require evidence of follicular pigmentation after 6 months (8-10 treatments/month) or claims will be denied. (3) Flag all experimental/investigational codes as NON-COVERED in billing system: CPT 0232T, 11920-11922, 15100-15101, 38225-38228, 76376-76377, 81291, 97810-97811; HCPCS A4633, J0139, J0636, J1438, J1745, J2501, J8522, J9312, P9020, Q5103-Q5145, S0161. (4) Deny all claims for micropigmentation (CPT 11920-11922) and depigmentation therapy as cosmetic. (5) Update encounter forms and provider education materials to list required pre-treatment steps before phototherapy approval. Notify all billing staff that claims without proper documentation of failed prior therapy will be denied and require resubmission.